Trial Profile
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim (AMG 531) Treatment of Subjects With Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2018
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary) ; Azacitidine; Decitabine
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Sponsors Amgen
- 18 Nov 2014 New trial record